A U.S. senator revealed how a GLP-1 drug transformed his life and is advocating for broader access to anti-obesity medications. In an op-ed for The New York Times on April 8, Senator John Fetterman, D-Pa., shared his experience with Mounjaro (tirzepatide), an injectable prescription primarily used to treat type 2 diabetes. Fetterman, a stroke survivor, was intrigued by research indicating that Mounjaro could significantly lower the risk of major cardiac events, leading to his prescription of the medication in July 2024.
The senator expressed how taking Mounjaro improved his overall well-being beyond heart health, relieving him of aches, pains, and stiffness, and making him feel physically rejuvenated and mentally sharper. Notably, he mentioned shedding around 20 pounds as a side effect. GLP-1 medications, such as Mounjaro and others like Ozempic and Wegovy, have shown benefits beyond blood sugar control, including enhanced heart health, cognitive function, and metabolic well-being.
Fetterman highlighted the need for expanded access to these medications, which can be costly for those without insurance coverage. While he emphasized the importance of nutrition and a healthy lifestyle, he stressed the indispensable role of medications for individuals facing serious health challenges. The senator urged for greater coverage under Medicare and Medicaid to ensure more people can benefit from these potentially life-changing drugs.
Dr. Marc Siegel, a clinical professor of medicine at NYU Langone Health and Fox News’ senior medical analyst, emphasized the importance of semaglutides, such as Ozempic and Wegovy, in the treatment of type 2 diabetes and obesity. He highlighted ongoing studies on the heart, lipid profile, brain health, and dementia risk associated with these drugs, emphasizing the need for more data. Lifestyle changes like exercise, diet improvement, and sufficient sleep are typically the first approach to addressing obesity, according to Siegel. However, he acknowledged that weight-loss medications like Zepbound can be valuable tools when lifestyle adjustments are insufficient. One individual, Fetterman, was prescribed Mounjaro for potential heart health benefits to prevent diseases related to obesity like heart disease, stroke, high blood pressure, and sleep apnea.
Dr. Brett Osborn, a Florida neurologist and longevity expert, spoke about the benefits of GLP-1 medications like Mounjaro in metabolic health. He emphasized that these medications are not just for weight loss but also serve as metabolic reset buttons, offering improvements in heart health, neurological function, and overall metabolic health. Osborn stressed the importance of these medications in helping patients with metabolic syndrome establish healthy habits and see the benefits of a healthier lifestyle.
Regarding coverage of these medications by Medicare and Medicaid, Osborn suggested that the recent decision not to cover them may be a negotiation tactic to lower prices. He believed that President Trump’s administration was sending a message to pharmaceutical companies to reduce prices or risk losing coverage by major buyers like Medicare. Osborn expressed optimism that negotiations could lead to more affordable options for patients while holding pharmaceutical companies accountable.
For more health-related articles, visit www.foxnews.com/health.
